This is a working overview of pentapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-11 and is reviewed periodically as new material appears.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Pentapeptide with C-terminal amide |
| Average mass | Approximately 711.9 Da | Value derived from the formula |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and aqueous acetonitrile | Dissolution aided by acidic diluents |
| Common synonyms | Ipamorelin; NNC 26-0161 | Code name used in early reports |
在 GHS 家族中，早期肽类如 GHRP-6 与 GHRP-2 会同时促进生长激素、皮质醇与催乳素的释放，并明显增加食欲。Ipamorelin 在动物与早期人体研究中表现出对生长激素释放的相对选择性，对上述其他激素的影响较小。这种差异通常归因于受体结合模式与下游信号偏向的不同，而完整的分子解释仍有待补充。需要区分的是，选择性是研究观察中的相对程度，并非绝对界限。
从用途定位看，ipamorelin 目前主要以研究用肽的身份被讨论，未见主要药品监管机构将其批准为治疗药物。市售材料通常标注仅供研究使用，不得用于人体或诊断程序。文献中它常与生长激素促分泌素、GHS-R1a 激动剂、胃饥饿素拟似物等表述并列出现。既有研究的样本量普遍偏小，因此对其效应强度与一致性的描述应保持谨慎。
Ipamorelin 是一种合成五肽，序列为 Aib-His-D-2-Nal-D-Phe-Lys-NH2，分子式 C38H49N9O5，游离碱分子量约 711.85 g/mol。它属于生长激素促分泌素（GHS）家族，作用靶点是胃饥饿素受体 GHS-R1a。该化合物由诺和诺德的研究团队在二十世纪九十年代末报道，设计目标是提高对生长激素释放的选择性。C 端酰胺化与 N 端 Aib 残基是两个用于抵抗肽酶降解的结构特征。
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
doi:10.1016/j.cell.2007.02.029. PMID 17350564. S2CID 14249277. Zaneveld J, Hamady M, Sueoka N, Knight R (28 February 2009). "CodonExplorer: An Interactive Online Database for the Analysis of Codon Usage and Sequence Composition". Bioinformatics for DNA Sequence Analysis. Methods in Molecular Biology. Vol. 537. pp. 207–232. doi:10.1007/978-1-59745-251-9_10. ISBN 978-1-58829-910-9. PMC 2953947. PMID 19378146.
Conservation of mass Conservation of energy Conservation of momentum The continuum assumption For example, the assumption that mass is conserved means that for any fixed control volume (for example, a spherical volume)—enclosed by a control surface—the rate of change of the mass contained in that volume is equal to the rate at which mass is passing through the surface from outside to inside, minus the rate at which mass is passing from inside to outside. This can be expressed as an equation in integral form over the control volume.
== Mission personnel == Astronaut: L. Gordon Cooper, Jr. Backup Astronaut: Alan Shepard Flight Director – Red Team: Chris Kraft Flight Director – Blue Team: John Hodge Mercury Seven group: In addition to Shepard, each of the original Mercury Seven astronauts supported the orbital journey of Mercury 9 - John Glenn on a command ship near Japan, Scott Carpenter in Hawaii, Gus Grissom at a tracking station in Mexico, Wally Schirra as capsule communicator at Mercury mission control at Cape Canaveral, and Deke Slayton as an observer at the Cape. Worldwide support teams: Because MA-9 would orbit over nearly every part of the world from 32.5 degrees north to 32.5 degrees south, a total of 28 ships, 171 aircraft, and 18,000 servicemen were assigned to support the mission.
Sources: en.wikipedia.org
During Bukele's presidency, El Salvador has hosted a number of international sporting events and one edition of the Miss Universe beauty pageant. Some experts have described El Salvador's hosting of such events as an attempt at sportswashing. Bukele has promoted surfing as part of El Salvador's tourism market. He designated part of El Salvador's Pacific coastline in the La Libertad Department as "Surf City", where the 2021 and 2023 ISA World Surfing Games were hosted. El Salvador also hosted the 2023 Central American and Caribbean Games. At the tournament's opening ceremony, Bukele rebuked critics by saying that he was "not a dictator" and told them to ask everyday Salvadorans what they thought about his "supposed dictatorship". In January 2023, Bukele announced that El Salvador would host the Miss Universe 2023 pageant; the last time El Salvador had hosted Miss Universe was in 1975. At the pageant, Bukele said that Miss Universe had given El Salvador the opportunity to "show the world what we are capable of". On the day of the pageant, 300 members of the Movement for Victims of the State of Emergency held a protest demanding the release of innocent victims of the country's gang crackdown and wanting "Miss Universe to see that Salvadorans are suffering". Some protestors wore sashes reading "Miss Political Prisoners", "Miss Persecution", and "Miss Mass Trials".
Half-Life is a series of first-person shooter games created and published by Valve. Since the release of the original Half-Life for Windows in 1998, several Half-Life projects have been canceled, including some developed by other studios. In 1999, Valve canceled a Half-Life port for Mac developed by Logicware. Half-Life: Hostile Takeover, an expansion pack for Half-Life developed by 2015, was cancelled in 2000. In 2001, Sierra, the publisher of the original Half-Life, canceled a port for Dreamcast after Sega announced its discontinuation. After releasing Half-Life 2: Episode Two in 2007, Valve struggled to settle on a direction for a new Half-Life game. Episode Three was canceled after Valve abandoned episodic development and began developing a new game engine, Source 2. Another Half-Life 2 episode, by Junction Point Studios, was canceled after Junction Point was acquired by Disney Interactive Studios. Valve moved the project to Arkane Studios, who developed it as Ravenholm, set in the town infested with zombies from Half-Life 2 (2004). Valve canceled it as they felt it was creatively restrained. Valve developed Half-Life 3 between 2013 and 2014, experimenting with procedurally generated levels, but canceled it as the Source 2 engine was still unfinished. A virtual reality (VR) game set on a time-travelling ship, Borealis, was canceled as the VR technology and tools were not complete. As of 2025, datamines and leaks suggested that a Half-Life game codenamed HLX was in development using Source 2.
===== Methane ===== Methane produced by marine methanogens is typically more D-enriched than methane produced by methanogens grown in freshwater. δDs for thermogenic methane range from −275‰ to −100‰, and from −400‰ to −150‰ for microbial methane.
The proportions [given by Webb] indicate that this might have been a squid-like form, and not an Octopus. The "breadth" is evidently that of the softened and collapsed body, and would represent an actual maximum diameter in life of at least 7 feet and a probable weight of 4 or 5 tons for the body and head. These dimensions are decidedly larger than those of any of the well-authenticated Newfoundland specimens. It is perhaps a species of Architeuthis. Verrill soon changed his mind about the identity of the creature. In the January 3 issue of the New York Herald, he wrote that the carcass was indeed that of a giant octopus. However, the paper did not state that Verrill was the author of the article. The article read:
Sources: en.wikipedia.org
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.
It has not received marketing approval as a medicine in the United States or the European Union. Supplied material is generally described and handled as a research chemical. Regulatory treatment varies by jurisdiction, and some countries restrict growth hormone secretagogues under sports or medicines legislation.
Earlier secretagogues were associated with broader hormonal responses, including measurable changes in cortisol and prolactin. Reports on this peptide describe a narrower profile in which growth hormone release is the most prominent effect. The observation is influential because it shapes how the compound is compared with other members of the same receptor family.
It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.